227 related articles for article (PubMed ID: 18217507)
1. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia.
Holden PK; Vokes DE; Taylor MB; Till JA; Crumley RL
Ann Otol Rhinol Laryngol; 2007 Dec; 116(12):891-6. PubMed ID: 18217507
[TBL] [Abstract][Full Text] [Related]
2. Combined modality treatment of adductor spasmodic dysphonia.
Silverman EP; Garvan C; Shrivastav R; Sapienza CM
J Voice; 2012 Jan; 26(1):77-86. PubMed ID: 21292439
[TBL] [Abstract][Full Text] [Related]
3. Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period.
Namin AW; Christopher KM; Eisenbeis JF
J Voice; 2017 Jan; 31(1):107-110. PubMed ID: 27005439
[TBL] [Abstract][Full Text] [Related]
4. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
[TBL] [Abstract][Full Text] [Related]
5. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
Cha W; Jang JY; Wang SG; Kang JH; Jo MG
J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
[TBL] [Abstract][Full Text] [Related]
6. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
[TBL] [Abstract][Full Text] [Related]
8. Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia.
Chang CY; Chabot P; Thomas JP
Otolaryngol Head Neck Surg; 2007 Jun; 136(6):894-9. PubMed ID: 17547976
[TBL] [Abstract][Full Text] [Related]
9. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
Sulica L; Blitzer A; Brin MF; Stewart CF
Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
Morzaria S; Damrose EJ
J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin therapy for abductor spasmodic dysphonia.
Woodson G; Hochstetler H; Murry T
J Voice; 2006 Mar; 20(1):137-43. PubMed ID: 16126369
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia.
Blitzer A
Otolaryngol Head Neck Surg; 2005 Dec; 133(6):836-8. PubMed ID: 16360499
[TBL] [Abstract][Full Text] [Related]
14. Onabotulinum toxin A dosage trends over time for adductor spasmodic dysphonia: A 15-year experience.
Tang CG; Novakovic D; Mor N; Blitzer A
Laryngoscope; 2016 Mar; 126(3):678-81. PubMed ID: 26308153
[TBL] [Abstract][Full Text] [Related]
15. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort.
French G; Bosch JD; Randall DR
J Otolaryngol Head Neck Surg; 2020 Jan; 49(1):4. PubMed ID: 31937363
[TBL] [Abstract][Full Text] [Related]
16. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
Young DL; Halstead LA
J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
[TBL] [Abstract][Full Text] [Related]
17. OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage.
Marchese MR; D'Alatri L; Bentivoglio AR; Paludetti G
Toxicon; 2018 Dec; 155():38-42. PubMed ID: 30315835
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment.
Langeveld TP; van Rossum M; Houtman EH; Zwinderman AH; Briaire JJ; Baatenburg de Jong RJ
Ann Otol Rhinol Laryngol; 2001 Jul; 110(7 Pt 1):627-34. PubMed ID: 11465821
[TBL] [Abstract][Full Text] [Related]
19. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
Meyer TK; Hu A; Hillel AD
Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
[TBL] [Abstract][Full Text] [Related]
20. Current practices in the management of adductor spasmodic dysphonia.
Eskander A; Fung K; McBride S; Hogikyan N
J Otolaryngol Head Neck Surg; 2010 Oct; 39(5):622-30. PubMed ID: 20828529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
